Recorded live at EAU26 in London, this special episode features a live recording of GU Cast, bringing a dynamic and interactive format to the congress stage.

Hosted by Prof. Declan Murphy (AU) and Prof. Renu Eapen (AU), the session brings together expert guests to discuss updates in prostate cancer guidelines, recent evidence, and key developments in urology. With contributions from the audience and a lively journal club segment, the episode offers a broad overview of current topics shaping clinical practice. Expect an engaging mix of expert insight, discussion and real-time interaction.

For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Recorded live at EAU26 in London, this special podcast episode features Prof. Brian Rini (US) and Prof. Tom Powles (GB) hosting an interactive UROmigos discussion with experts from the audience.

The session explores evolving treatment strategies and key debates in bladder and kidney cancer, highlighting emerging evidence and its potential impact on clinical decision-making.

For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

In this episode, UROONCO RCC chief editor Dr. Carmen Mir talks to Prof. Jose Karam on the results of the LITESPARK-022 study: Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC): The randomised phase 3 LITESPARK-022 study.

The LITESPARK-022 study will be also presented and discussed at the upcoming EAU26 on Saturday 14th March in the Game Changer Session. Don't miss the chance to hear more on this important study.

This interview was recorded at ASCO GU26. For more updates on kidney cancer, please visit our educational platform UROONCO RCC.

For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Prostate surgery in the United Kingdom was the domain of general surgeons for a relatively long time, discover why in this podcast. On the other hand, the UK has been leading the professionalisation and organisation of urological nurses. Both topics (and more) are the major topics at this year’s Historical Exhibition, part of the EAU Square (V14) in the EAU26 Exhibition.

Author and historian Mr. Loek Keizer (NL) of the EAU Central Office talks to urological surgeon and member of the EAU History Office Mr. Jonathan Goddard (GB) about that Office’s activities in London during EAU26.

• Visit the Abstract Session mentioned in the podcast.
• Prof. Van Kerrebroeck’s talk
• Mr. Goddard’s talk.

For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

In this episode, UROONCO BCa chief editor Dr Benjamin Pradere (France) sits down with Matthew Galsky, Professor of Medicine at Icahn School of Medicine at Mount Sinai (New York, USA), to discuss the newly published results of the KEYNOTE-B15 trial.

This marks a truly pivotal moment for muscle-invasive bladder cancer. The presentation of KEYNOTE-B15 represents one of the most practice-changing advances in localised MIBC management in recent years, opening a new era of peri-operative systemic therapy and renewed hope for our patients.

KEYNOTE-B15 is a randomised phase III trial evaluating peri-operative enfortumab vedotin plus pembrolizumab in cisplatin-eligible patients with MIBC. In this in-depth discussion, Prof. Galsky walks us through the scientific rationale behind the study, the key efficacy and safety results, and crucially, how these data are likely to reshape clinical practice, not only in the immediate future but for years to come.
A must-listen conversation for urologists and multidisciplinary teams involved in the care of bladder cancer patients.

The KEYNOTE-B15 study will be also presented and discussed at upcoming EAU26 on Saturday 14th March in the Game Changer Session. Don't miss the chance to hear more on this important study and mark your agenda!

This interview was recorded at ASCO GU26. For more updates on bladder cancer, please visit our educational platform UROONCO BCa.

For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

In this Journal Club edition of the EAU Podcast, Prof. Thomas Tailly leads a focused discussion on the recently completed APPEAL trial, a multicentre randomised controlled study evaluating whether routine antibiotic prophylaxis is necessary for patients undergoing extracorporeal shock wave lithotripsy (ESWL).

The distinguished panel - Prof. Kari Tikkinen, Prof. Zafer Tandogdu, Dr. Daron Smith, and Dr. Guido Kamphuis - explores the study’s design, recruitment challenges, outcome measures and the rationale behind examining antibiotic use in a procedure historically considered low-risk for infection.

They discuss variations in practice across centres, the balance between preventing rare infectious complications and avoiding unnecessary antibiotic exposure, and how the trial contributes valuable evidence in an area with limited high-quality data.

Throughout the episode, the panel reflects on how these findings align with current EAU recommendations and considers how the APPEAL trial can support future refinements in guideline statements. With a mix of expert insight, clinical reasoning and constructive debate, this episode offers listeners a clear understanding of the trial’s significance and its potential impact on everyday urological practice.

You can find the article to the APPEAL trial here.

For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

In Episode 1, “Understanding EU-ACME / MyCME in daily practice” of the series “Start smart: EU-ACME for young urologists”, Prof. Marek Babjuk, Assoc. Prof. Juan Luis Vásquez, Prof. Giorgio Ivan Russo and Dr. Loïc Baekelandt introduce the EU-ACME programme and its role in supporting structured training and professional development.

They clarify key concepts, terminology, and membership types, helping listeners build a strong foundation for engaging with the system. Their discussion highlights how EU-ACME contributes to harmonising education and promoting high standards across European urology.

For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

In this episode, UROONCO PCa associate editor Prof. Claudia Kesch (DE) interviews Dr. Jochen Walz (FR) about the key highlights of 2025 in low- to intermediate-risk prostate cancer.

They discuss advances in imaging diagnostics, artificial intelligence and biomarkers, active surveillance, surgical techniques and radiotherapy, as well as what is anticipated in 2026.

Here are the links to the articles and interviews on the trials which were mentioned in this podcast:

• OPTIMUM Trial
• PRIME Trial
• BARCODE1 study
• NeuroSAFE PROOF trial results
• ENZARAD trial

For more updates on prostate cancer, please visit our educational platform UROONCO PCa.

For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.